Melbourne, Australia, 28 November 2025 – Cartherics Pty Ltd (“Cartherics” or “Company”), a biotechnology company developing off-the-shelf immune cell therapies focusing on high-impact women’s diseases, with lead programs in ovarian […]
Cartherics is pleased to announce that it will be presenting at the 8th Australian and New Zealand Society for Extracellular Vesicles (ANZSEV) 2025 Conference in Wellington, New Zealand. ANZSEV 2025 will showcase advances in the field across EVs and biological nanoparticles – their role in cell biology, advances in technologies for their purification and […]
Cartherics is proud to announce the successful certification of our new clean room facility, marking a significant milestone in our journey toward delivering off-the-shelf cell therapies for cancer and endometriosis.
This milestone builds on the recent unveiling of our cleanroom facility, as announced here, and reflects our continued progress in […]
Today, Cartherics proudly hosted a Frocktober Afternoon Tea in support of ovarian cancer awareness and research. Frocktober is a meaningful initiative that encourages us to go the extra style mile – turning heads, starting conversations, and raising vital funds for ovarian cancer research.
We were honoured to welcome Robin Penty, CEO of the Ovarian Cancer Research […]
Cartherics’ COO, Dr Ian Nisbet recently joined Xtalks’ Life Science Podcast to discuss Cartherics’ vision for next generation cell therapies.
He discussed how Cartherics’ platform is building an effectively unlimited supply of CAR NK cells and exploring treatments for underserved conditions like cancer and endometriosis. Dr Nisbet also reflects on his biotech leadership […]
Melbourne, Australia, 11 September 2025 – Cartherics Pty Ltd (“Cartherics” or “Company”), a biotechnology company developing off-the-shelf immune cell therapies focusing on high-impact women’s diseases, with lead programs in ovarian cancer and endometriosis, is proud to announce that it has been named ‘Most Promising iPSC Therapy Pipeline in APAC’ in the Asia Pacific Cell […]
Cartherics is proud to share that our CEO, Professor Alan Trounson, was recently interviewed on 10 News+ by journalists Amelia Brace and Denham Hitchcock.
In the interview, Prof. Trounson provided an in-depth look at Cartherics’ world-first immunotherapies and how this innovative science is shaping the future of treatment for some of the most difficult-to-treat diseases.
Our lead […]
Melbourne, Australia, 27 August 2025 – Cartherics Pty Ltd (“Cartherics” or “Company”), a biotechnology company developing off-the-shelf immune cell therapies focusing on high-impact women’s diseases, with lead programs in ovarian cancer and endometriosis, today announced the granting of a patent for ‘Method for Providing Immune Cells with Enhanced Function’ by the Chinese Patent Office.
This […]
Melbourne, Australia, 6 August 2025 – Cartherics Pty Ltd (“Cartherics” or “Company”), a biotechnology company developing off-the-shelf immune stem cell therapies focusing on high-impact women’s diseases, with lead programs in ovarian cancer and endometriosis, today unveiled its new, state-of-the-art cleanroom facility for clinical-scale manufacturing of cell therapy products.
The facility was officially opened by the […]
Cartherics is pleased to announce that Mathew Tiedemann has officially completed his PhD, a major milestone in an already impressive scientific journey! His thesis titled, ‘Developing a Clinically Translatable iPSC-derived Immunotherapy’ focused on designing clinically relevant methods to create billions of gene-edited blood cells from stem cells to better detect and destroy ovarian cancer.
Mat’s key […]
Cartherics’ mission is the development of novel, immune cell therapy products for the treatment of cancer, endometriosis and Alzheimer’s disease.
Stay informed about our latest news and developments
© Copyright 2022 | Cartherics Pty ltd
